How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,074 results for

Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines

Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Last updated: August 1, 2019 Project Number: RA1056-000 Product Line: Research Type: Drug Report Type

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) Full Text available with Trip Pro

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) | Journal for ImmunoTherapy of Cancer | Full Text Advertisement Search Search all BMC articles Search The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (...) (RCC) , , , , , , , , , , , , , , , , & volume 7 , Article number: 354 ( 2019 ) 5049 Accesses 144 Altmetric Abstract The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018

2020 Society for Immunotherapy of Cancer

3. Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness

Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Oral Immunotherapy for Food Oral Immunotherapy Protocols (...) for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Last updated: November 2, 2018 Project Number: RB1272-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of oral immunotherapy (OIT) for food allergy in children? Key Message Six randomized controlled trials and two non-randomized studies were identified regarding the clinical effectiveness of oral immunotherapy (OIT) for food

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) Full Text available with Trip Pro

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) | Journal for ImmunoTherapy of Cancer | Full Text Advertisement Search Search all BMC articles Search The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment (...) for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating

2019 Society for Immunotherapy of Cancer

5. Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. Full Text available with Trip Pro

Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. IgE-mediated food allergy remains a significant and growing problem across the globe. Of the various treatment modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best studied. Across various studies of OIT for egg, milk, and peanut allergy, strong levels of desensitization have been shown. With egg and peanut OIT, a limited remission, or sustained unresponsiveness (SU), has (...) ; however, the adequacy of its desensitization has remained to be determined. As OIT and EPIT continue their march toward regulatory review, optimizations for immunotherapy and novel therapies continue to be developed providing hope for food allergy patients everywhere.© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2020 Allergy

6. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. (Abstract)

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Neuroblastoma is a rare malignant disease that primarily affects children. The tumours mainly develop in the adrenal medullary tissue, and an abdominal mass is the most common presentation. High-risk disease is characterised by metastasis and other primary tumour characteristics resulting in increased risk for an adverse (...) outcome. The GD2 carbohydrate antigen is expressed on the cell surface of neuroblastoma tumour cells and is thus a promising target for anti-GD2 antibody-containing immunotherapy.To assess the efficacy of anti-GD2 antibody-containing postconsolidation immunotherapy after high-dose chemotherapy (HDCT) and autologous haematopoietic stem cell transplantation (HSCT) compared to standard therapy after HDCT and autologous HSCT in people with high-risk neuroblastoma. Our primary outcomes were overall

2019 Cochrane

7. EAN MS & Immunology Scientific Panel: Immunotherapy for patients with neuroimmunological disorders during the COVID-19 pandemic

EAN MS & Immunology Scientific Panel: Immunotherapy for patients with neuroimmunological disorders during the COVID-19 pandemic 1 Immunotherapy for patients with neuroimmunological disorders during the COVID-19 pandemic Immunotherapy for patients with neuroimmunological disorders during the COVID-19 pandemic 24. March 2020 Corona Virus Disease 2019 (COVID-19) is a new illness caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which typically causes (...) for guidance on the use of therapies during the COVID-19 pandemic. There are now numerous recommendations circulating, especially by national and international societies for distinct diseases, that attempt to provide clarity and guidance. There are differences among the recommendations that have created confusion and immunotherapy decision making varies significantly from country to country, ranging from highly provider-directed to a more collaborative decision-making model. EAN here provides some general

2020 European Academy of Neurology

8. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Full Text available with Trip Pro

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 | Journal for ImmunoTherapy of Cancer Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Article Text This article has a correction. Please see: Editorial Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

2020 Society for Immunotherapy of Cancer

9. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Full Text available with Trip Pro

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response | Journal for ImmunoTherapy of Cancer Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Article Text Position article and guidelines The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related

2020 Society for Immunotherapy of Cancer

10. Antigen-specific active immunotherapy for ovarian cancer. Full Text available with Trip Pro

Antigen-specific active immunotherapy for ovarian cancer. This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9).Despite advances in chemotherapy, the prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce tumour antigen-specific anti-tumour immune responses as an alternative treatment for ovarian cancer.Primary objective• To assess the clinical efficacy of antigen-specific active (...) immunotherapy for the treatment of ovarian cancer as evaluated by tumour response measured by Response Evaluation Criteria In Solid Tumors (RECIST) and/or cancer antigen (CA)-125 levels, response to post-immunotherapy treatment, and survival differences◦ In addition, we recorded the numbers of observed antigen-specific humoral and cellular responsesSecondary objective• To establish which combinations of immunotherapeutic strategies with tumour antigens provide the best immunological and clinical results

2018 Cochrane

11. A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Full Text available with Trip Pro

A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Aims: Allergic rhinitis is caused by sensitivity to environmental allergens that can significantly impact quality-of-life. The objective of this analysis was to estimate health state utilities and quality-adjusted life days (QALDs) for a tree allergy immunotherapy trial, TT-04 (EudraCT No.2015-004821-15). Health-state utilities are a measure of patient (...) preference for health states and are necessary to derive QALDs for cost-utility analysis. Preference-based utilities were not collected in the TT-04 trial, so a mapping algorithm was developed based on a similar grass allergy immunotherapy trial, GT-08 (EudraCT No. 2004-000083-27), to estimate utilities.Methods: A two-part model was developed to predict utilities for the GT-08 trial and applied to the TT-04 trial to estimate the difference in mean utility and QALDs between SQ tree sublingual

2020 Journal of medical economics Controlled trial quality: uncertain

12. Advances in the management of peanut allergy (oral immunotherapy and epicutaneous immunotherapy). (Abstract)

Advances in the management of peanut allergy (oral immunotherapy and epicutaneous immunotherapy). Background: Peanut allergy affects up to 2% of the general population and carries not only the risk of potentially life-threatening allergic reactions but also negatively impacts day to day life for patients and their families. Advances in knowledge in immunotherapy is providing families with options for proactive treatment. Objective: To examine the available data for oral immunotherapy (OIT (...) ) and epicutaneous immunotherapy (EPIT) for peanut allergy. Methods: This review discusses recent studies that evaluated the safety and efficacy of OIT and EPIT to induce desensitization to peanut and identifies factors that should be considered when guiding families in treatment decisions. Results: Results of studies have demonstrated that immunotherapy can raise the threshold of peanut allergen to induce allergic reactions for many patients, thereby potentially reducing the risk for allergic reactions

2020 Allergy and Asthma Proceedings

13. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. (Abstract)

Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. In 2004, it was estimated that one fatal anaphylactic reaction (FR) occurred in every 2.4 million subcutaneous immunotherapy (SCIT) injection visits. Uncontrolled asthma was the most commonly cited factor that contributed to FRs. Results of the annual American College of Allergy, Asthma, and Immunology/American Academy (...) factors for SRs: a history of SRs to SCIT, the administration of injections in patients with uncontrolled asthma, use of accelerated buildup regimens, and never adjusting doses during the height of the allergy season. Delayed-onset SRs beginning >30 minutes after injections represented 15% of all SRs in clinics with 30-minute observation periods. The safety profile of sublingual immunotherapy is favorable, with no FRs yet identified for sublingual tablet or liquid formulations. Risk management should

2020 Allergy and Asthma Proceedings

14. NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness

NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness | CADTH.ca Find the information you need NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness Last updated: November 15, 2018 Project Number: RA0989-000 Product (...) Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer? Key Message No relevant literature was identified regarding the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer. Files Rapid Response Reference List Published : November 15, 2018 Related Content Follow us: © 2019 Canadian Agency for Drugs

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost (...) -Effectiveness and Guidelines Last updated: October 4, 2018 Project Number: RB1264-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of oral immunotherapy for food allergy in children? What is the cost-effectiveness of oral immunotherapy for food allergy in children? Key Message Three systematic reviews with meta-analyses, thirteen randomized-controlled studies, one economic evaluation, and three evidence

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. ASCIA Guide - Aeroallergen Immunotherapy

ASCIA Guide - Aeroallergen Immunotherapy Aeroallergen Immunotherapy A Guide for Clinical Immunology/Allergy Specialists This document supersedes information contained in the 2015 ASCIA Allergen Immunotherapy Manual. It has been updated by the ASCIA Immunotherapy Working Party and extracted into this separate Guide. ASCIA Immunotherapy Working Party members are listed on the ASCIA website www.allergy.org.au/members/committees#wpim ASCIA resources are based on published literature and expert (...) review. ASCIA health professional document references are at www.allergy.org.au/hp/papers Abbreviations AIT Allergen immunotherapy LLR Large local reaction AlOH Aluminium hydroxide (Alum) MCT Mast cell tryptase AR Adverse reaction NSP Normal saline with phenol BAT Basophil activation tests PBS Pharmaceutical Benefits Scheme, AU CCD Common carbohydrate determinants Pharmac Pharmaceutical Management Agency, NZ DBPC Double blind placebo controlled PRP Pathogenesis-related protein DF Dermatophagoides

2019 Australasian Society of Clinical Immunology and Allergy

18. ASCIA Guide - Venom Immunotherapy

ASCIA Guide - Venom Immunotherapy ASCIA Venom Immunotherapy Guide 1 Venom Immunotherapy A Guide for Clinical Immunology/Allergy Specialists This document supersedes information contained in the older 2014 ASCIA Allergen Immunotherapy Manual. It has been updated by the ASCIA Immunotherapy Working Party and extracted into this separate Guide. ASCIA Immunotherapy Working Party members are listed on the ASCIA website. ASCIA resources are based on published literature and expert review. ASCIA health (...) professional document references are at www.allergy.org.au/hp/papers Abbreviations CCD Common carbohydrate determinants GMP Good manufacturing practice IDT Intradermal test IgE Immunoglobulin E IgG Immunoglobulin G JJA Jack Jumper Ant MCT Mast cell tryptase PBS Pharmaceutical Benefits Scheme, AU Pharmac Pharmaceutical Management Agency, NZ QOL Quality of life SCIT Subcutaneous immunotherapy sIgE (allergen) specific IgE SPT Skin prick test SR Systemic reactions TGA Therapeutic Goods Administration, AU VIT

2019 Australasian Society of Clinical Immunology and Allergy

19. Immunotherapy for diabetic amyotrophy. Full Text available with Trip Pro

Immunotherapy for diabetic amyotrophy. People with diabetes mellitus (DM) sometimes present with acute or subacute, progressive, asymmetrical pain and weakness of the proximal lower limb muscles. The various names for the condition include diabetic amyotrophy, diabetic lumbosacral radiculoplexus neuropathies, diabetic femoral neuropathy or Bruns-Garland syndrome. Some studies suggest that diabetic amyotrophy may be an immune-mediated inflammatory microvasculitis causing ischaemic damage (...) of the nerves. Immunotherapies would therefore be expected to be beneficial. This is the second update of a review first published in 2009.To review the evidence from randomised trials for the efficacy of any form of immunotherapy in the treatment of diabetic amyotrophy.On 5 September 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We also contacted authors of relevant publications and other experts to obtain additional references, unpublished trials

2017 Cochrane

20. Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies

Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Rationale: CAR T cells and genetically engineered TCR T cells are targeted, personalized therapies for malignancies and other neoplastic disorders, including hematological cancers

2018 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>